Middle East Pharmaceutical Industries Company
4016.SRSAUHealthcare● Active
$62.10
$-0.20(-0.32%)
Market Cap$2.2B
P/E Ratio—
52W High$79.08572
52W Low$53.88572
Middle East Pharmaceutical Industries Company (4016.SR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
4016.SR · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.77
Revenue
$0.13B
Est. $0.13B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
4016.SR reports quarterly as a SAU-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 6, 2026 | — | $0.77 | — | $0.13B | $0.13B | +0.0% |
| — Q1 FY2026 | Mar 4, 2026 | $2.27 | $2.27 | +0.0% | $0.14B | $0.14B | -4.1% |
| — Q4 FY2025 | Nov 5, 2025 | — | $0.23 | — | $0.11B | $0.10B | +2.9% |
| — Q3 FY2025 | Aug 10, 2025 | — | $0.71 | — | $0.12B | $0.12B | +2.3% |
| — Q2 FY2025 | May 12, 2025 | — | $0.55 | — | $0.10B | $0.10B | +1.6% |
| — Q1 FY2025 | Feb 18, 2025 | — | $1.28 | — | $0.14B | $0.14B | -5.9% |
| — Q4 FY2024 | Nov 7, 2024 | — | $0.11 | — | $0.08B | $0.08B | -2.0% |
| — Q3 FY2024 | Aug 5, 2024 | — | $0.62 | — | $0.10B | $0.11B | -7.1% |
Q2 FY2026
May 6, 2026
EPS Actual
$0.77
EPS Est.
—
EPS Surpr.
—
Revenue
$0.13B
Q1 FY2026
Mar 4, 2026
EPS Actual
$2.27
EPS Est.
$2.27
EPS Surpr.
+0.0%
Revenue
$0.14B
Q4 FY2025
Nov 5, 2025
EPS Actual
$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
$0.11B
Q3 FY2025
Aug 10, 2025
EPS Actual
$0.71
EPS Est.
—
EPS Surpr.
—
Revenue
$0.12B
Q2 FY2025
May 12, 2025
EPS Actual
$0.55
EPS Est.
—
EPS Surpr.
—
Revenue
$0.10B
Q1 FY2025
Feb 18, 2025
EPS Actual
$1.28
EPS Est.
—
EPS Surpr.
—
Revenue
$0.14B
Q4 FY2024
Nov 7, 2024
EPS Actual
$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Q3 FY2024
Aug 5, 2024
EPS Actual
$0.62
EPS Est.
—
EPS Surpr.
—
Revenue
$0.10B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $1.30 | $1.30 | $1.30 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2025 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2024 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 6, 2026 | — | $58.06 | $59.89 | +3.15% |
| ▲ Q1 FY2026 | Mar 4, 2026 | +0.0% | $56.86 | $58.74 | +3.31% |
| — Q4 FY2025 | Nov 5, 2025 | — | $74.29 | $72.57 | -2.32% |
| — Q3 FY2025 | Aug 10, 2025 | — | $67.54 | $70.06 | +3.73% |
| — Q2 FY2025 | May 12, 2025 | — | $71.66 | $72.91 | +1.74% |
| — Q1 FY2025 | Feb 18, 2025 | — | $77.83 | $79.43 | +2.06% |
| — Q4 FY2024 | Nov 7, 2024 | — | $75.66 | $74.63 | -1.36% |
| — Q3 FY2024 | Aug 5, 2024 | — | $67.43 | $64.23 | -4.75% |
Q2 FY2026+3.15%
Report Date
May 6, 2026
EPS Beat/Miss
—
Price Before
$58.06
Price After
$59.89
Q1 FY2026+3.31%
Report Date
Mar 4, 2026
EPS Beat/Miss
+0.0%
Price Before
$56.86
Price After
$58.74
Q4 FY2025-2.32%
Report Date
Nov 5, 2025
EPS Beat/Miss
—
Price Before
$74.29
Price After
$72.57
Q3 FY2025+3.73%
Report Date
Aug 10, 2025
EPS Beat/Miss
—
Price Before
$67.54
Price After
$70.06
Q2 FY2025+1.74%
Report Date
May 12, 2025
EPS Beat/Miss
—
Price Before
$71.66
Price After
$72.91
Q1 FY2025+2.06%
Report Date
Feb 18, 2025
EPS Beat/Miss
—
Price Before
$77.83
Price After
$79.43
Q4 FY2024-1.36%
Report Date
Nov 7, 2024
EPS Beat/Miss
—
Price Before
$75.66
Price After
$74.63
Q3 FY2024-4.75%
Report Date
Aug 5, 2024
EPS Beat/Miss
—
Price Before
$67.43
Price After
$64.23
Avg Beat Reaction+3.31%
Beat Rate1 / 8 quarters
Largest Move-4.75% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: 4016.SR ends December
Middle East Pharmaceutical Industries Company (4016.SR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.77 (in line with the analyst consensus of —). The next 4016.SR earnings date is expected around September 2, 2026.
Each quarter, investors track 4016.SR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. 4016.SR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
4016.SR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
4016.SR earnings · 4 questionsMiddle East Pharmaceutical Industries Company's next earnings report is expected around September 2, 2026. 4016.SR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; 4016.SR historically reports after market close (AMC).
4016.SR earnings datewhen is 4016.SR earnings4016.SR next earnings datewhen does 4016.SR report earnings4016.SR earnings calendar
▸ Source: FMP · Middle East Pharmaceutical Industries Company SEC filings · US GAAP · Middle East Pharmaceutical Industries Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026